A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma

Inclusion Criteria:

* Written informed consent by and HIPAA authorization for release of personal health information obtained from the research participant.
* Able to speak and read English to a sufficient level of fluency to provide informed consent and complete the study questionnaires.
* Age ≥ 18 years at the time of consent.
* ECOG Performance Status of ≤ 3 within 28 days prior to consent.
* Histological or cytologically confirmed urothelial carcinoma.
* Patients must be planned to start systemic therapy with enfortumab vedotin
* At time of enrollment, patients must be planned to start enfortumab with or without pembrolizumab

Exclusion Criteria:

Subjects meeting any of the criteria below may not participate in the study:

* Inability of the subject to understand and comply with study procedures.
* Having previously received enfortumab vedotin
* Students/employees of the study institution, pregnant women, prisoners, and institutionalized individuals (to prevent enrollment of vulnerable subjects).